GenAns Biotech is a next-generation gene therapy company focused on central nervous system (CNS) and ophthalmic diseases. We bring together a diverse team of scientists, drug developers, business leaders, and advisors from academia and the biotech industry to advance research and development in gene therapy. With a strong commitment to scientific innovation and clinical translation, GenAns explores potential therapeutic approaches for diseases with significant unmet medical needs. Our long-term vision is to translate advances in life sciences into meaningful possibilities for human health.
AAV High-Throughput Directed Evolution Screening Platform：
The AAV High-Throughput Directed Evolution Screening Platform is based on rational design and high-throughput screening technologies. It is designed to develop and evaluate gene delivery vectors, explore their cell- or tissue-specific delivery capabilities, and provide technical support for the development of disease-related candidate medicines.
Functional Protein Screening Platform:
The Functional Protein Screening Platform applies rational design and mutant library construction, combined with high-throughput screening and evolution technologies based on all-optical logic gates and microfluidic chips. Guided by target functions, the platform enables the screening and optimization of specific functional proteins and supports functional studies and safety evaluation of candidate medicines.
Neurological Drug Discovery and Evaluation Platform:
The Drug Development Platform is built on principles of physiology and neuroscience, integrating neural circuit research and biomedical big data. By applying genetic, pharmacological, and physicochemical approaches, the platform supports drug discovery and evaluation across multiple scales, including molecular, cellular, tissue, organ, and physiological levels, and enables candidate screening, mechanism-of-action studies, and subsequent development.
Pipeline information
We have established multiple investigational new drug pipelines focusing on common and major brain diseases.
Our research teams are working to advance investigational programs for patients affected by these challenging conditions.
Sensory system diseases
Investigational programs related to sensory system diseases.
Organic brain disease
Investigational programs related to organic brain diseases.
Degenerative brain disease
Investigational programs related to degenerative brain diseases.
Severe mental illness
Investigational programs related to severe mental disorders.
malignant brain tumor
Investigational programs related to malignant brain tumors..
GenAns has raised 100 million yuan in Pre-A round financing.
